// App-Quantinova.ai

524 : Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer receiving immune check-point inhibitors – applicability and potential caveats

Researchers

Presenter

  • Line Nederby

Principal Investigators

  • Sinne Brun

  • Torben Hansen

  • Christa Nyhus

  • Lisbeth Bertelsen

  • Rikke Andersen

  • Anders Jakobsen

Medical Centers

  • University Hospital of Southern Denmark, Vejle, Denmark

Locations

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Soluble programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved